Novel manganese-zinc ferrite nanoparticles can potentially be used in cancer treatment

NewsGuard 100/100 Score

A group of Russian scientists has synthesized manganese-zinc ferrite nanoparticles that can potentially be used in cancer treatment. Due to their unique magnetic properties, the particles can serve as deactivators of affected cells while having almost no negative impact on healthy tissues. The results have been published in the Journal of Sol-Gel Science and Technology.

One of the most important global goals in today's medicine is finding ways to combat cancer. Currently, there are several kinds of treatments with differing effectiveness and various side effects. In most cases, the treatment causes harmful impact not only to cancer cells but also the adjacent healthy tissues or the body at large.

Magnetic fluid hyperthermia is a promising method that can help alleviate the side effects of cancer treatment. This method involves introducing a magnetic nanoparticles-containing sol into a tumor followed by its exposure to a variable magnetic field. This causes the heating of the nanoparticles and leads to the deactivation of cancer cells. However, the majority of the materials used for this purpose are toxic to the body. What is more, the particles continue to heat up to relatively high temperatures, which entails serious damage to healthy tissues.

These problems could be solved by the application of special nanoparticles which can change their magnetic properties depending on the temperature. In physics, there is such a notion as the Curie temperature (also known as the Curie point), which is the temperature at which a sharp decrease in magnetization is observed.

When the Curie temperature is reached, a ferromagnetic changes into a paramagnetic, consequently the particles cease to be as susceptible to the magnetic field and their further heating stops. When the temperature drops back again, the particles resume their heating. Essentially, we observe a self-management of temperature in a narrow range. If we select a composition that experiences such a transition at the temperature we need, then it could prove effective for magnetic fluid hyperthermia."

Vasilii Balanov, a Master's student at ITMO University and one of the research's authors

Choosing the material, the scientists opted for ferrites - compounds of iron oxide (III)Fe2O3 with oxides of other metals. Generally, thanks to their properties, these materials are widely applied in computer technologies, but, as it turned out, they can also be used for medical purposes.

"We took the particles with the general formula Zn(x)Mn(1-x)Fe2O4, in which zinc and manganese are selected in a certain proportion," expounds Vasilii Balanov. "They don't have a toxic effect on the body, and with the right ratio of manganese and zinc we were able to achieve a Curie temperature in the range of 40-60 degrees Celsius. This temperature allows us to deactivate cancer cells, concurrently, the short-term thermal contact is relatively harmless to healthy tissues."

As of now, the scientists have already synthesized the nanoparticles and studied their magnetic properties. The experiments confirmed that the material doesn't heat up above 60 degrees Celsius when exposed to a variable magnetic field. Coming next will be the experiments on living cells and, if these are successful, on animals.

Source:
Journal reference:

Balanov, V.A., et al. (2020) Synthesis of (Mn(1−x)Znx)Fe2O4 nanoparticles for magnetocaloric applications. Journal of Sol-Gel Science and Technology. doi.org/10.1007/s10971-020-05237-8.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer